Veterinary Surgical Oncology. Группа авторов
haemangiosarcoma. Vet Comp Oncol 8:221–233.
748 Willard, M.D., H. Tvedten, R. Walshaw, et al. 1980. Thymoma in a cat. J Am Vet Med Assoc 176:451–453.
749 Williams, L.E., J.M. Gliatto, R.K. Dodge, et al. 2003. Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985–1995). J Am Vet Med Assoc 223:825–831.
750 Williams, L.E., J.L. Johnson, M.L. Hauck, et al. 2004. Chemotherapy followed by half‐body radiation therapy for canine lymphoma. J Vet Intern Med 18:703–709.
751 Williams, L.E., A.F. Pruitt, and D.E. Thrall. 2010. Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma. Vet Radiol Ultrasound 51:681–687.
752 Wilson, H.M., R. Chun, V.S. Larson, et al. 2007. Clinical signs, treatments, and outcome in cats with transitional cell carcinoma of the urinary bladder: 20 cases (1990–2004). J Am Vet Med Assoc 231:101–106.
753 Withrow, S.J., E.L. Gillette, P.J. Hoopes, et al. 1989. Intraoperative irradiation of 16 spontaneously occurring canine neoplasms. Vet Surg 18:7–11.
754 Withrow, S.J., J.M. Liptak, R.C. Straw, et al. 2004. Biodegradable cisplatin polymer in limb‐sparing surgery for canine osteosarcoma. Ann Surg Oncol 11:705–713.
755 Withrow, S.J., D.E. Thrall, R.C. Straw, et al. 1993. Intra‐arterial cisplatin with or without radiation in limb‐sparing for canine osteosarcoma. Cancer 71:2484–2490.
756 Wood, C.A., A.S. Moore, J.M. Gliatto, et al. 1998. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991–1993). J Am Anim Hosp Assoc 34:417–421.
757 Worth, A.J., R.M. Zuber, and M. Hocking. 2005. Radioiodide (131I) therapy for the treatment of canine thyroid carcinoma. Aust Vet J 83:208–214.
758 Wouda, R.M., J. Borrego, N.S. Keuler, et al. 2016. Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs. Vet Comp Oncol 14:67–80.
759 Wouda, R.M., M.E. Miller, E. Chon, et al. 2015. Clinical effects of vinorelbine administration in the management of various malignant tumor types in dogs: 58 cases (1997–2012). J Am Vet Med Assoc 246:1230–1237.
760 Wycislo, K.L. and T.M. Fan. 2015. The immunotherapy of canine osteosarcoma: A historical and systematic review. J Vet Intern Med 29:759–769.
761 Yamagami, T., T. Kobayashi, K. Takahashi, et al. 1996. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. J Small Anim Pract 37:462–464.
762 Yokoe, I., K. Azuma, K. Hata, et al. 2015. Clinical systemic lupeol administration for canine oral malignant melanoma. Mol Clin Oncol 3:89–92.
763 Yoon, H.Y. and F.A. Mann. 2008. Bilateral pubic and ischial osteotomy for surgical management of caudal colonic and rectal masses in six dogs and a cat. J Am Vet Med Assoc 232:1016–1020.
764 Yu, S., K.J. Wedekind, P.A. Burris, et al. 2011. Controlled level of dietary iodine normalizes serum total thyroxine in cats with naturally occurring hyperthyroidism (abstract). J Vet Intern Med 25:683–684.
765 Zandvliet, M., G.R. Rutteman, and E. Teske. 2013. Prednisolone inclusion in a first‐line multidrug cytostatic protocol for the treatment of canine lymphoma does not affect therapy results. Vet J 197:656–661.
766 Zemann, B.I., A.S. Moore, W.M. Rand, et al. 1998. A combination chemotherapy protocol (Velcap‐L) for dogs with lymphoma. J Vet Intern Med 12:465–470.
767 Zenker, I., K. Meichner, K. Steinle, et al. 2010. Thirteen‐week dose‐intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs. Vet Rec 167:744–748.
768 Zitz, J.C., S.J. Birchard, G.C. Couto, et al. 2008. Results of excision of thymoma in cats and dogs: 20 cases (1984–2005). J Am Vet Med Assoc 232:1186–1192.
3 Interventional Oncology
William T.N. Culp
Interventional radiology (IR) is a specialty that uses different imaging modalities to direct minimally invasive diagnostic and therapeutic procedures. IR has become a well‐established and integral specialty in human medicine and is rapidly growing in veterinary medicine. The influx of IR techniques in veterinary medicine allows veterinary clinicians the ability to offer patients advanced treatment options that were previously unavailable. Interventional oncology (IO) is a subspecialty of IR that is focused on the treatment of oncologic diseases.
When performing IO procedures, it is essential for the veterinary clinician to have a firm grasp of different imaging modalities and basic surgical procedures, as surgically approaching blood vessels is often necessary. IO procedures such as vascular stenting, intraarterial chemotherapy, and transarterial embolization/chemoembolization are performed intravascularly, and specialized sheaths, guidewires, and catheters are needed for these interventions. Nonvascular diseases such as malignant obstructions and effusions can also be treated with IO techniques and involve the placement of stents and long‐term catheters.
Many of the current applications of IO in veterinary patients are palliative; in these cases, the primary goal is to improve the quality of life while causing minimal morbidity. IO can also provide treatment options in cases that were previously considered untreatable. Reports on the use of IO in veterinary patients are limited, but investigation of IO applications in human medicine offers insight into the vast benefits that this expanding specialty can offer for our veterinary patients. A systematic discussion of the imaging, instrumentation, and techniques involved in IO will be discussed below.
Imaging
Complete knowledge of the vascular anatomy is mandatory for performing vascular interventions. Additionally, the interventional radiologist should have a thorough understanding of the imaging modalities and contrast agents that are used to perform IO procedures. While imaging modalities such as fluoroscopy, computed tomography (CT), and magnetic resonance imaging (MRI) are commonly employed by veterinary clinicians, the use of these modalities for IO treatments is largely unreported, aside from isolated case reports and small case series.
Modalities
Stenting procedures can be performed solely with digital radiography, although fluoroscopy is superior, as it allows for real‐time evaluation of the anatomy. Fluoroscopy is mandatory when performing IO procedures that require vascular interventions. A fluoroscopy unit (C‐arm) with specifications including digital subtraction, road‐mapping ability, collimation, and low patient radiation dosing is ideal. Ceiling mounting should be pursued when possible, and the C‐arm should have the ability to acquire complex oblique views. Newer units allow the interventional radiologist to perform image acquisition and most other C‐arm operations at the bedside, eliminating the need for an assistant to perform these tasks in a control room. Recently, the angiographic anatomy of the abdominal arterial blood supply was reported to provide a guide to individuals that are performing interventional procedures related to the abdominal organs (Culp et al. 2015a). Additionally, that study determined common locations for vascular branching.
While angiography performed with fluoroscopic guidance allows for excellent evaluation of the direction and velocity of blood flow, the images obtained are in two‐dimensional planes and only display the lumen of the vessel (Green and Parker 2003). Computed tomographic angiography (CTA) and magnetic resonance angiography (MRA) are rapidly developing imaging modalities that have certain advantages over fluoroscopy, including noninvasive angiographic image acquisition, less patient postprocedure discomfort, and volumetric and cross‐sectional image analysis (Green and Parker 2003; Hellinger and Rubin 2006; Thornton and Grist 2006). The volumetric and cross‐sectional image analysis that is obtained with CTA and MRA allows vessels to be evaluated in multiple directions with a single scan, whereas several images and injections of contrast are necessary to gain the same information using fluoroscopy (Hellinger and Rubin 2006). Advances are being made that